Martin ZapataLaguado· @zapatalaguadomd · X·· 1 day agoScore70
Body · original
#ESMO26 | VOLGA in cisplatin-ineligible MIBC: Durvalumab + enfortumab vedotin significantly improved: OS: HR 0.58 (p=0.0027) EFS: HR 0.51 (p<0.0001) 2-year OS: 78% vs 69%ctDNA clearance: 60%
A major advance in MIBC@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily
41 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Martin ZapataLaguado · x.com